{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:09:02Z","timestamp":1757455742054,"version":"3.37.3"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"MSD Portugal"},{"name":"MSD Spain"},{"name":"Spanish Network for Research in Infectious Diseases","award":["RD16\/0016\/0001","RD16\/0016\/0004","RD16\/0016\/0006","RD16\/0016\/0007","RD16\/0016\/0010","REIPI RD16\/0016\/0011"],"award-info":[{"award-number":["RD16\/0016\/0001","RD16\/0016\/0004","RD16\/0016\/0006","RD16\/0016\/0007","RD16\/0016\/0010","REIPI RD16\/0016\/0011"]}]},{"DOI":"10.13039\/501100008530","name":"ERDF","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To study the in vitro activity of imipenem\/relebactam and comparators and the imipenem\/relebactam resistance mechanisms in a Pseudomonas aeruginosa collection from Portugal (STEP, 2017\u201318) and Spain (SUPERIOR, 2016\u201317) surveillance studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>P. aeruginosa isolates (n\u200a=\u200a474) were prospectively recovered from complicated urinary tract (cUTI), complicated intra-abdominal (cIAI) and lower respiratory tract (LRTI) infections in 11 Portuguese and 8 Spanish ICUs. MICs were determined (ISO broth microdilution). All imipenem\/relebactam-resistant P. aeruginosa isolates (n\u200a=\u200a30) and a subset of imipenem\/relebactam-susceptible strains (n\u200a=\u200a32) were characterized by WGS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Imipenem\/relebactam (93.7% susceptible), ceftazidime\/avibactam (93.5% susceptible) and ceftolozane\/tazobactam (93.2% susceptible) displayed comparable activity. The imipenem\/relebactam resistance rate was 6.3% (Portugal 5.8%; Spain 8.9%). Relebactam restored imipenem susceptibility to 76.9% (103\/134) of imipenem-resistant isolates, including MDR (82.1%; 32\/39), XDR (68.8%; 53\/77) and difficult-to-treat (DTR) isolates (67.2%; 45\/67). Among sequenced strains, differences in population structure were detected depending on the country: clonal complex (CC)175 and CC309 in Spain and CC235, CC244, CC348 and CC253 in Portugal. Different carbapenemase gene distributions were also found: VIM-20 (n\u200a=\u200a3), VIM-1 (n\u200a=\u200a2), VIM-2 (n\u200a=\u200a1) and VIM-36 (n\u200a=\u200a1) in Spain and GES-13 (n\u200a=\u200a13), VIM-2 (n\u200a=\u200a3) and KPC-3 (n\u200a=\u200a2) in Portugal. GES-13-CC235 (n\u200a=\u200a13) and VIM type-CC175 (n\u200a=\u200a5) associations were predominant in Portugal and Spain, respectively. Imipenem\/relebactam showed activity against KPC-3 strains (2\/2), but was inactive against all GES-13 producers and most of the VIM producers (8\/10). Mutations in genes affecting porin inactivation, efflux pump overexpression and LPS modification might also be involved in imipenem\/relebactam resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Microbiological results reinforce imipenem\/relebactam as a potential option to treat cUTI, cIAI and LRTI caused by MDR\/XDR P. aeruginosa isolates, except for GES-13 and VIM producers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac298","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T05:11:12Z","timestamp":1662354672000},"page":"3163-3172","source":"Crossref","is-referenced-by-count":15,"title":["<i>In vitro<\/i> activity of imipenem\/relebactam against <i>Pseudomonas aeruginosa<\/i> isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2857-2572","authenticated-orcid":false,"given":"Marta","family":"Hern\u00e1ndez-Garc\u00eda","sequence":"first","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal-IRYCIS , Madrid , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-Castillo","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal-IRYCIS , Madrid , Spain"}]},{"given":"Jos\u00e9","family":"Melo-Cristino","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Microbiologia Centro Hospitalar Universit\u00e1rio Lisboa Norte , Lisboa , Portugal"}]},{"given":"Margarida F","family":"Pinto","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Microbiologia, Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar Universit\u00e1rio Lisboa Central , Lisboa , Portugal"}]},{"given":"Elsa","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Microbiologia Cl\u00ednica Centro Hospitalar de Lisboa Ocidental , Lisboa , Portugal"}]},{"given":"Valqu\u00edria","family":"Alves","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Microbiologia, Unidade Local de Sa\u00fade de Matosinhos , Matosinhos , Portugal"}]},{"given":"Ana Raquel","family":"Vieira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o , Porto , Portugal"}]},{"given":"Elmano","family":"Ramalheira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o Patologia Cl\u00ednica, Hospital Infante Dom Pedro , Aveiro , Portugal"}]},{"given":"Lu\u00edsa","family":"Sancho","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Hospital Prof. Dr. Fernando da Fonseca , Amadora , Portugal"}]},{"given":"Jos\u00e9","family":"Diogo","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Microbiologia, Hospital Garcia de Orta , Almada , Portugal"}]},{"given":"Rui","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica\u2013Microbiologia, CHUA\u2013Unidade de Portim\u00e3o , Portim\u00e3o , Portugal"}]},{"given":"Hugo","family":"Cruz","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Microbiologia do Centro Hospitalar Universit\u00e1rio do Porto , Porto , Portugal"}]},{"given":"Catarina","family":"Chaves","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Microbiologia, Centro Hospitalar Universit\u00e1rio de Coimbra , Coimbra , Portugal"}]},{"given":"Germ\u00e1n","family":"Bou","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario A Coru\u00f1a , A Coru\u00f1a , Spain"}]},{"given":"Emilia","family":"Cercenado","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Mara\u00f1\u00f3n , Madrid , Spain"},{"name":"CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III , Madrid , Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-2620","authenticated-orcid":false,"given":"Mercedes","family":"Delgado-Valverde","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"UGC Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen Macarena\/CSIC\/Universidad de Sevilla , Sevilla , Spain"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Son Espases , Palma de Mallorca , Spain"}]},{"given":"Cristina","family":"Pitart","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Cl\u00ednic i Provincial , Barcelona , Spain"}]},{"given":"Jes\u00fas","family":"Rodr\u00edguez-Lozano","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Marqu\u00e9s de Valdecilla , Santander , Spain"}]},{"given":"Nuria","family":"Tormo","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Consorcio Hospital General Universitario de Valencia , Valencia , Spain"}]},{"given":"Jazm\u00edn","family":"D\u00edaz-Rega\u00f1\u00f3n","sequence":"additional","affiliation":[{"name":"Departamento M\u00e9dico, MSD Espa\u00f1a , Madrid , Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-2495","authenticated-orcid":false,"given":"Leonor","family":"P\u00e1ssaro","sequence":"additional","affiliation":[{"name":"MSD Portugal , Pa\u00e7o de Arcos , Portugal"}]},{"given":"Joana","family":"Duarte","sequence":"additional","affiliation":[{"name":"MSD Portugal , Pa\u00e7o de Arcos , Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-3173","authenticated-orcid":false,"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal-IRYCIS , Madrid , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}]},{"name":"STEP and SUPERIOR study groups","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[]},{"given":"Xavier","family":"Mulet","sequence":"additional","affiliation":[]},{"given":"Emilia","family":"Cercenado","sequence":"additional","affiliation":[]},{"given":"Germ\u00e1n","family":"Bou","sequence":"additional","affiliation":[]},{"given":"M Carmen","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[]},{"given":"\u00c1lvaro","family":"Pascual","sequence":"additional","affiliation":[]},{"given":"Mercedes","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Concepci\u00f3n","family":"Gimeno","sequence":"additional","affiliation":[]},{"given":"Nuria","family":"Tormo","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Calvo","sequence":"additional","affiliation":[]},{"given":"Jes\u00fas","family":"Rodr\u00edguez-Lozano","sequence":"additional","affiliation":[]},{"given":"Ana \u00c1vila","family":"Alonso","sequence":"additional","affiliation":[]},{"given":"Jordi","family":"Vila","sequence":"additional","affiliation":[]},{"given":"Francesc","family":"Marco","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Pitart","sequence":"additional","affiliation":[]},{"given":"Mar\u00eda Garc\u00eda","family":"del Castillo","sequence":"additional","affiliation":[]},{"given":"Sergio","family":"Garc\u00eda-Fern\u00e1ndez","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Hern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[]},{"given":"Jazm\u00edn","family":"D\u00edaz-Rega\u00f1\u00f3n","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"2022102819183211800_dkac298-B1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1473-3099(10)70258-9","article-title":"Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study","volume":"11","author":"Lambert","year":"2011","journal-title":"Lancet Infect Dis"},{"author":"ECDC","key":"2022102819183211800_dkac298-B2"},{"key":"2022102819183211800_dkac298-B3","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/jiw299","article-title":"Host and pathogen biomarkers for severe Pseudomonas aeruginosa infections","volume":"215","author":"Juan","year":"2017","journal-title":"J Infect Dis"},{"key":"2022102819183211800_dkac298-B4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa \u2013 mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resist Updat"},{"key":"2022102819183211800_dkac298-B5","doi-asserted-by":"crossref","first-page":"e00031-19","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2022102819183211800_dkac298-B6","doi-asserted-by":"crossref","first-page":"106196","DOI":"10.1016\/j.ijantimicag.2020.106196","article-title":"Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update","volume":"56","author":"Barrio-Tofi\u00f1o","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2022102819183211800_dkac298-B7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21\u201322","author":"Oliver","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2022102819183211800_dkac298-B8","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/IDR.S224228","article-title":"A clinical review and critical evaluation of imipenem-relebactam: evidence to date","volume":"13","author":"Campanella","year":"2020","journal-title":"Infect Drug Resist"},{"key":"2022102819183211800_dkac298-B9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem\u2013relebactam and meropenem\u2013vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"2022102819183211800_dkac298-B10","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2022102819183211800_dkac298-B11","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819183211800_dkac298-B12","doi-asserted-by":"crossref","first-page":"105887","DOI":"10.1016\/j.ijantimicag.2020.105887","article-title":"In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: the STEP multicenter study","volume":"55","author":"Garc\u00eda-Fern\u00e1ndez","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2022102819183211800_dkac298-B13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijantimicag.2019.02.004","article-title":"Activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: the SUPERIOR multicentre study","volume":"53","author":"Garc\u00eda-Fern\u00e1ndez","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2022102819183211800_dkac298-B14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/jac\/dkaa430","article-title":"Distinct epidemiology and resistance mechanisms affecting ceftolozane\/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS","volume":"76","author":"Hern\u00e1ndez-Garc\u00eda","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022102819183211800_dkac298-B15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2022102819183211800_dkac298-B16","first-page":"1803","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022102819183211800_dkac298-B17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/jac\/dkab496","article-title":"Comparative analysis of in vitro dynamics and mechanisms of ceftolozane\/tazobactam and imipenem\/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones","volume":"77","author":"Gomis-Font","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2022102819183211800_dkac298-B18","doi-asserted-by":"crossref","first-page":"e00181-19","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"de Oliveira","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2022102819183211800_dkac298-B19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2022102819183211800_dkac298-B20","doi-asserted-by":"crossref","first-page":"e02209-16","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819183211800_dkac298-B21","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/jac\/dkz191","article-title":"Activity of imipenem\/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015\u201317","volume":"74","author":"Lob","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022102819183211800_dkac298-B22","doi-asserted-by":"crossref","first-page":"e02165-19","DOI":"10.1128\/AAC.02165-19","article-title":"Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic-lactam-resistant mutants","volume":"64","author":"Fraile-Ribot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819183211800_dkac298-B23","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1093\/jac\/dkaa206","article-title":"In vitro dynamics and mechanisms of resistance development to imipenem and imipenem\/relebactam in Pseudomonas aeruginosa","volume":"75","author":"Gomis-Font","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022102819183211800_dkac298-B24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/2049-632X.12033","article-title":"Pseudomonas aeruginosa: new insights into pathogenesis and host defenses","volume":"67","author":"Gellatly","year":"2013","journal-title":"Pathog Dis"},{"key":"2022102819183211800_dkac298-B25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tim.2011.04.005","article-title":"Pseudomonas aeruginosa: all roads lead to resistance","volume":"19","author":"Breidenstein","year":"2011","journal-title":"Trends Microbiol"},{"key":"2022102819183211800_dkac298-B26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.cmi.2017.06.018","article-title":"Global emergence of the widespread Pseudomonas aeruginosa ST235 clone","volume":"24","author":"Treepong","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2022102819183211800_dkac298-B27","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1128\/JCM.00753-11","article-title":"Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals","volume":"49","author":"Garc\u00eda-Castillo","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2022102819183211800_dkac298-B28","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/AAC.01720-16","article-title":"Deciphering the resistome of the widespread Pseudomonas sequence type 175 international high-risk clone through whole-genome sequencing","volume":"60","author":"Cabot","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819183211800_dkac298-B29","doi-asserted-by":"crossref","first-page":"e01007-20","DOI":"10.1128\/mSystems.01007-20","article-title":"Phenotypic and genomic comparison of the two most common ExoU-positive Pseudomonas aeruginosa clones, PA14 and ST235","volume":"5","author":"Fischer","year":"2020","journal-title":"mSystems"},{"key":"2022102819183211800_dkac298-B30","doi-asserted-by":"crossref","first-page":"106026","DOI":"10.1016\/j.ijantimicag.2020.106026","article-title":"Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2","volume":"56","author":"P\u00e9rez-V\u00e1zquez","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2022102819183211800_dkac298-B31","doi-asserted-by":"crossref","first-page":"e01117-20","DOI":"10.1128\/AAC.01117-20","article-title":"Mechanisms of resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa: results of the GERPA multicenter study","volume":"65","author":"Fournier","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819183211800_dkac298-B32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/jac\/dkx517","article-title":"Two decades of blaVIM-2-producing Pseudomonas aeruginosa dissemination: an interplay between mobile genetic elements and successful clones","volume":"73","author":"Botelho","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/11\/3163\/46680465\/dkac298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/11\/3163\/46680465\/dkac298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:22:51Z","timestamp":1666984971000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/11\/3163\/6691802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,5]]},"published-print":{"date-parts":[[2022,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac298","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2022,11,2]]},"published":{"date-parts":[[2022,9,5]]}}}